Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age

Simple item page
dc.catalogadorjwg
dc.contributor.authorPapazisis, Georgios
dc.contributor.authorTopalidou, Xanthippi
dc.contributor.authorGioula, Georgia
dc.contributor.authorGonzález, Pablo A.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis Parra, Alexis Mikes
dc.date.accessioned2024-04-03T16:31:15Z
dc.date.available2024-04-03T16:31:15Z
dc.date.issued2024
dc.description.abstractImmunosenescence refers to age-related alterations in immune system function affecting both the humoral and cellular arm of immunity. Understanding immunosenescence and its impact on the vaccination of older adults is essential since primary vaccine responses in older individuals can fail to generate complete protection, especially vaccines targeting infections with increased incidence among the elderly, such as the respiratory syncytial virus. Here, we review clinical trials of both candidate and approved vaccines against respiratory syncytial virus (RSV) that include adults aged ≥50 years, with an emphasis on the evaluation of immunogenicity parameters. Currently, there are 10 vaccine candidates and 2 vaccines approved for the prevention of RSV in the older adult population. The number of registered clinical trials for this age group amounts to 42. Our preliminary evaluation of published results and interim analyses of RSV vaccine clinical trials indicates efficacy in older adult participants, demonstrating immunity levels that closely resemble those of younger adult participants.
dc.fuente.origenORCID
dc.identifier.doi10.3390/vaccines12040353
dc.identifier.urihttps://www.mdpi.com/2076-393X/12/4/353
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84919
dc.identifier.wosidWOS:001210369700001
dc.information.autorucEscuela de Medicina; Kalergis Parra, Alexis Mikes; 0000-0001-7622-5263; 90610
dc.language.isoen
dc.nota.accesocontenido completo
dc.revistaVaccines
dc.rightsacceso abierto
dc.subjectImmunosenescence
dc.subjectInflammaging
dc.subjectRespiratory syncytial virus
dc.subjectAging
dc.subjectElderly
dc.subjectClinical trials
dc.subjectVaccinology
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleRespiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age
dc.typeartículo
sipa.codpersvinculados90610
sipa.trazabilidadORCID;2024-04-01
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-12-00353.pdf
Size:
322.01 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas